{
  "id": "mhgap#risk_safety_95b0bbf4",
  "content": "placebo for adults with anxiety disorders (excluding social anxiety\ndisorders and specific phobias)?\nRecommendation (new): Benzodiazepines are not recommended for the treatment of adults with\ngeneralized anxiety disorder (GAD) and/or panic disorder. For emergency\nmanagement of acute and severe anxiety symptoms, benzodiazepines may\nbe considered but only as a short-term (3–7 days maximum) measure.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification period requires monitoring and follow-up by trained\ny Evidence was extracted from three systematic specialist providers and is beyond the scope of\nreviews: Slee et al., 2019 (89 RCTs on this guideline.\npharmacological interventions for adults with\nResearch gaps\nGAD) (34); Breilmann et al., 2019 (24 RCTs on\ny The majority of studies were conducted in\nbenzodiazepines for adults with panic disorder)\nHICs. Further research is needed to enhance\n(46); and Shinfuku et al., 2019 (8 RCTs on long-term\nunderstanding on use in low-resource settings.\noutcomes for adults with anxiety disorders following\nbenzodiazepine use) (47). y There is a limited number of studies on the long-\nterm effectiveness and safety of benzodiazepines.\ny Low-quality evidence suggests reduced levels of\nFurther research would help to quantify the risks of\nanxiety and improved functioning in adults with",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "medium",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety placebo for adults with anxiety disorders (excluding social anxiety\ndisorders and specific phobias)?\nRecommendation (new): Benzodiazepines are not recommended for the treatment of adults with\ngeneralized anxiety disorder (GAD) and/or panic disorder. For emergency\nmanagement of acute and severe anxiety symptoms, benzodiazepines may\nbe considered but only as a short-term (3–7 days maximum) measure.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification period requires monitoring and follow-up by trained\ny Evidence was extracted from three systematic specialist providers and is beyond the scope of\nreviews: Slee et al., 2019 (89 RCTs on this guideline.\npharmacological interventions for adults with\nResearch gaps\nGAD) (34); Breilmann et al., 2019 (24 RCTs on\ny The majority of studies were conducted in\nbenzodiazepines for adults with panic disorder)\nHICs. Further research is needed to enhance\n(46); and Shinfuku et al., 2019 (8 RCTs on long-term\nunderstanding on use in low-resource settings.\noutcomes for adults with anxiety disorders following\nbenzodiazepine use) (47). y There is a limited number of studies on the long-\nterm effectiveness and safety of benzodiazepines.\ny Low-quality evidence suggests reduced levels of\nFurther research would help to quantify the risks of\nanxiety and improved functioning in adults with Placebo for adults with lo âu disorders (excluding social lo âu\ndisorders and specific phobias)? recommendation (new): benzodiazepines are not recommended for the treatment of adults with\ngeneralized lo âu disorder (gad)..."
}